Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Aug 31;14(8):2895-2899.
doi: 10.21037/tlcr-2025-432. Epub 2025 Aug 13.

XPO1 inhibition in KRAS-mutant cancers: time for clinical trials but how?

Misako Nagasaka  1 , Husain Y Khan  2 , Faustine Luo  1 , Mohammed Najeeb Al-Hallak  2 , Muhammad Wasif Saif  2 , Ramzi M Mohammad  2 , Asfar S Azmi  2
Affiliations
Editorial

XPO1 inhibition in KRAS-mutant cancers: time for clinical trials but how?

Misako Nagasaka et al. Transl Lung Cancer Res. .
No abstract available

Keywords: KRAS inhibitors; eltanexor; non-small cell lung cancer (NSCLC); nuclear export; selinexor.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2025-432/coif). M.N. has received consulting fees from AstraZeneca, Caris Life Sciences, Daiichi Sankyo, Novartis, EMD Serono, Pfizer, Lilly and Genentech; has received travel support from AnHeart Therapeutics; and is a speaker for Takeda, Janssen, Mirati and Blueprint Medicines. A.S.A. received funding from Purple Biotec, FanWave Therapeutics, Colorado Chromatography, RLL and Blackstone Therapeutics; and is a council member at GLG and Guidepoint. The other authors have no conflicts of interest to declare.

Comment in

Comment on

References

    1. Su PL, Furuya N, Asrar A, et al. Recent advances in therapeutic strategies for non-small cell lung cancer. J Hematol Oncol 2025;18:35. 10.1186/s13045-025-01679-1 - DOI - PMC - PubMed
    1. Shahnam A, Davis A, Brown LJ, et al. Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations. Lung Cancer 2025;201:108421. 10.1016/j.lungcan.2025.108421 - DOI - PubMed
    1. von Itzstein MS, Burns TF, Dowell JE, et al. Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res 2025;31:639-48. 10.1158/1078-0432.CCR-24-1722 - DOI - PMC - PubMed
    1. Yang Y, Guo L, Chen L, et al. Nuclear transport proteins: structure, function, and disease relevance. Signal Transduct Target Ther 2023;8:425. 10.1038/s41392-023-01649-4 - DOI - PMC - PubMed
    1. Azmi AS, Uddin MH, Mohammad RM. The nuclear export protein XPO1 - from biology to targeted therapy. Nat Rev Clin Oncol 2021;18:152-69. 10.1038/s41571-020-00442-4 - DOI - PubMed